A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.
Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.
For two days, innovation in synthetic and bio-based fine chemicals will be in the focus of experts who meet at Chemspec Europe in Cologne (20-21 June, 2018, Koelnmesse).
Three years ago Roche acquired a majority in shares of Foundation Medicines Inc (FMI), a specialist in cancer panel sequencing, which has build a huge database with cancer mutation profiles. Now Roche paid US2.4bn to complete the take-over.
Researchers at French antibiotics specialist Deinobiotics SAS, a subsidiary of Deinove SA, and German researchers announces the discovery of a new class of resistance breaking antibiotics that kill MRSA or S. pneumoniae effectively.
Following a letter of about 1,000 EPO patent examiners , also patent attorneys have send an open letter to the European Patent Office (EPO), criticising its outgoing president for having established work routines that are set to lower quality of European patents.
Adrenomed AG announced the publication of three scientific papers revealing how its adrenomedullin-targeting Phase II sepsis antibody Adrecizumab reverses vascular hyperpermeability in sepsis.
As first regulatory body in the world, the FDA has presented a market-driven reimbursement mechanism for antibiotics that may incentivise drug development in a niche market with currently low return on investment.
Despite a 6-month improvement of 2-year-overall survival in pancreatic cancer patients, Norwegian cancer immunotherapy specialist Targovax ASA will terminate development of TG01 in this indication. Instead, development of RAS neoantigen-targeting cancer vaccines will be pushed in colorectal cancer.
British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price.